Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03147989 · ClinicalTrials.gov registry record
Retrospective Study of MRI With MULTIHANCE at 0.10 and 0.05 mmol/Kg Dose in CNS Patients
A clinical trial, sponsored by Bracco Diagnostics.
- Completed
- Registry status
- 352
- Enrollment target
NCT03147989: Completed study, sponsored by Bracco Diagnostics.
NCT03147989 is a clinical trial that has completed, run by Bracco Diagnostics. The registered enrollment target is 352 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03147989 has completed, sponsored by Bracco Diagnostics.
- COMPLETED
- Registry status
- 352 participants
- Enrollment target
Study Summary
This is a retrospective study to collect already existing data and images from patients ≥ 2 years of age who had MRI for CNS diseases with MultiHance administration at a standard 0.10 mmol/kg dose or the half dose of 0.05 mmol/kg. The MRI images of all included patients will be prospectively reviewed in a blinded read to compare the efficacy of the two doses.
Primary Outcome
To show non-inferiority of a 0.05 mmol/kg dose of MULTIHANCE as compared to 0.10 mmol/kg dose of MULTIHANCE, in patients undergoing contrast-enhanced MRI of the CNS in terms of lesion visualization based on pre-dose + post-dose: Border delineation of lesions
Interventions
- DRUG MultiHance
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 352 participants |
| Start Date | 2017-05-18 |
| Est. Completion | 2018-03-16 |
What the finished NCT03147989 record still lists
NCT03147989 is an observational study that tracks outcomes without assigning an intervention. The registered 352 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which MultiHance is the first listed.
NCT03147989 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03147989 about?
NCT03147989 is a clinical study titled "Retrospective Study of MRI With MULTIHANCE at 0.10 and 0.05 mmol/Kg Dose in CNS Patients". This is a retrospective study to collect already existing data and images from patients ≥ 2 years of age who had MRI for CNS diseases with MultiHance administration at a standard 0.10 mmol/kg dose or the half dose of 0.05 mmol/kg. The MRI images of all included patients will be prospectively reviewe...
What is the current status of trial NCT03147989?
This trial is currently completed. The enrollment target is 352 participants. The study started on 2017-05-18. Estimated completion is 2018-03-16.
What interventions are being tested in trial NCT03147989?
The interventions under investigation include: MultiHance (DRUG).
Who is sponsoring clinical trial NCT03147989?
This trial is sponsored by Bracco Diagnostics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05811936 · 352 participants · NA
The SNAP Tool for Head and Neck Cancer Survivor-Caregiver Dyads
- NCT06258941 · 352 participants · Phase 1
Classroom Break, Cognition, and Fitness in Elementary School Children
- NCT06269081 · 352 participants · NA
Testing Two Interventions to Improve Health Outcomes and Quality of Life Among Rural Older Adults Living With HIV
- NCT06337292 · 352 participants · Phase 3
Incisional Negative Pressure Wound Therapy to Reduce Infection and Complications in High-Risk Fractures
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI